Abstract
Autophagy is a cellular mechanism that degrades damaged or unwanted material from cells and is particularly important during ageing. Autophagy has been widely studied in pre-clinical models and is known to respond to nutrient availability and in particular amino acids. However, clinical data are limited. This protocol paper describes a randomized cross-over clinical study investigating the effect of a four-week long reduction of dietary protein intake on autophagic flux (autophagic degradative activity) measured via a blood test in healthy adults. Sixty-one healthy participants will be recruited. Study participants will be randomly assigned to one of two diets for four weeks, then cross over to the other diet with a four-week washout period between diets. The diets will be: 1) Average Protein Diet: a control comparator diet with a macronutrient profile of 20% of energy from protein, 35% from fat (<10% saturated) and 45% from carbohydrate, with >30 g of fiber/day; 2) Reduced Protein Diet: 10% protein, 35% fat (<10% saturated), 55% carbohydrate, >30 g of fiber/day. This diet will provide 0.7 g of protein per kg of body weight (the recommended minimum daily protein intake). The primary outcome will be the change in autophagic flux between each diet. This study aims to determine whether reducing dietary protein intake in healthy adults can increase autophagy in humans. If positive, it creates the possibility that nutritional strategies could be used to prevent or delay autophagy- related diseases such as Alzheimer disease or atherosclerosis.
Competing Interest Statement
TJS and JB are listed as inventors on a related patent: Australia (Provisional) 2019903187; 2019904822; PCT/AU/2020/050908; United Kingdom GB2603664B; USA 17/637,494.
Funding Statement
This work is supported by Lysosomal Health in Ageing at SAHMRI and the BrightFocus Foundation, USA (A2021040S). The funders have no role in study design, data collection and analysis, and in the decision to publish or the preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee (HREC) of the University of Adelaide on 31st August 2021 (HREC reference number: H-2021-154, current version at submission of this paper: v5.2 dated 30th May 2024) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No data are reported in this manuscript.
